Davidson Kempner Capital Management LP Sigilon Therapeutics, Inc. Transaction History

Davidson Kempner Capital Management LP

  • $2.97 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021
BUY
$27.6 - $48.03 $276,000 - $480,300
10,000 New
10,000 $474,000

About Sigilon Therapeutics, Inc.

SGTX Quotes by TradingView
  • Ticker SGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,399,300
  • Description
  • Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...
More about SGTX
Track This Portfolio

Track Davidson Kempner Capital Management LP Portfolio

Follow Davidson Kempner Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Davidson Kempner Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Davidson Kempner Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email